Objective: Elevated serum uric acid were related not only with cardiovascular disease but also with higher incident of chronic kidney disease in many cohort studies. Lower eGFR and higher urine albumin to creatine ratio (UACR) are associated with all-cause and cardiovascular mortality as well as future renal end-stage. Febxostat (FBX) and topiroxostat (TPX), new xanthine oxidase inhibitors with much less side effects as comparison to allopurinol, are available now. To demonstrate the effects of FBX and TPX on renal functions (eGFR and UACR) in well-controlled hypertensive patients. Design and method: We retrospectively collected 252 well-controlled hypertensive patients with hyperuricemia (HU) who newly received a prescription of FBX or TPX and continued 24 weeks without the addition of any other drugs. Those who had other uric acid-lowering drugs, diabetes mellitus or severe proteinuria were excluded. Total 252 Participants were selected and divided into FBX (128 patients) group and TPX (124 patients) group, both of who were matched for % mean dose/dairy conventional dose, age, sex, uric acid (UA), blood pressure (BP), UACR and eGFR. The changes of UA, BP, eGFR and UACR were evaluated between at the baseline and at the 24-week treatment by FBX and TPX. Results: The baseline characteristics were not significantly different between both treatment groups, which were analyzed by Mann-Whitney U test. Administration of FBX and TPX lowered UA significantly (p < 0.0001). Decrements of UA in both group were not significantly different. Diastolic BP of FBX group was only significantly reduced (BP129.3 ± 17.8/78.7 ± 12.4 mmHg to BP126.1 ± 16.3/76.2 ± 11.1 mmHg, p = 0.049). The eGFR in both FBX group and TPX group were significantly increased from 55.2 ± 15.0 to 56.8 ± 15.7 mL/min/1.73m2 (p = 0.0082) and from 57.3 ± 16.3 to 61.5 ± 16.3 mL/min/1.73m2 (p = 0.0002), respectively. In TPX and FBX groups, there were no significant differences in change of eGFR between patients using high and low amount of TPX and FBX, respectively. UACR was significantly decreased only in TPX group(90.0 ± 336 mg/gCr to 48.9 ± 171 mg/gCr, p = 0.027), while UACR in FBX group was not reduced (113 ± 376 mg/gCr to 120 ± 488 mg/gCr). Conclusions: FBX could improve eGFR and diastolic BP, and TPX could renoprotectively reduce UACR as well as increase eGFR.